IGC Pharma Targets Alzheimer’s Agitation With New Therapeutic Approach

Apr 16, 2026

IGC Pharma is developing innovative therapies focused on reducing agitation in Alzheimer’s patients, one of the most challenging and disruptive symptoms of the disease. By addressing both patient needs and caregiver burden, the company is targeting a critical gap in current treatment options.

With a focus on underserved areas of care, IGC Pharma aims to improve quality of life for patients and families while advancing new solutions in the fight against Alzheimer’s disease.

#IGCPharma
#Alzheimers
#MentalHealth
#Biotech
#HealthcareInnovation
#MedicalResearch
#Neuroscience
#DrugDevelopment
#Caregiving
#ClinicalTrials
#Pharmaceuticals
#NeurodegenerativeDisease
#Innovation
#Healthcare
#NewsOut